SCHEMBL23906103

SCHEMBL23906103

CC(C)c1nc(OC2CCC(C(=O)O)CC2)c2cc3[nH]ncc3cc2c1-c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 5/20 0.39
ADORA2A P29274 1/20 0.34
KCNH2 Q12809 1/20 0.34
SGK1 O00141 5/20 0.34
MAPK1 P28482 1/20 0.34
ABL1 P00519 4/20 0.33
PRKAG1 P54619 1/20 0.33
PRKAA1 Q13131 1/20 0.33
PRKAB1 Q9Y478 1/20 0.33
VCP P55072 1/20 0.33
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
PIK3CD O00329 1/20 0.33
RPS6KB1 P23443 1/20 0.33
GRK2 P25098 1/20 0.33
GRK5 P34947 1/20 0.33
ROCK1 Q13464 1/20 0.33
RPS6KA1 Q15418 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30251968 0.92 MAPK1 (0.34) SGK1MAPK1CTNNB1WNT3ARPS6KB1
SCHEMBL23884510 0.92 MAPK1 (0.34) SGK1MAPK1CTNNB1WNT3ARPS6KB1
SCHEMBL23905473 0.92 MAPK1 (0.34) SGK1MAPK1CTNNB1WNT3ARPS6KB1
SCHEMBL25474974 0.89 ROCK1 (0.34) DGAT1MAPK1CTNNB1WNT3ARPS6KB1
SCHEMBL23906298 0.85 MAPK1 (0.33) SGK1MAPK1CTNNB1WNT3ARPS6KB1
SCHEMBL25474971 0.85 ROCK1 (0.36) MAPK1CTNNB1WNT3ARPS6KB1GRK2
SCHEMBL23906108 0.84 CTNNB1 (0.33) MAPK1CTNNB1WNT3ARPS6KB1GRK2
SCHEMBL23906107 0.84 CTNNB1 (0.33) MAPK1CTNNB1WNT3ARPS6KB1GRK2
SCHEMBL23905499 0.84 GRIA1 (0.34) DGAT1KCNH2SGK1
SCHEMBL23884765 0.84 GRIA1 (0.34) DGAT1KCNH2SGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 DGAT1 2259/4885ADORA2A 2558/4885KCNH2 1541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.